Rezulin News Timeline

1997

January - Rezulin is approved by the FDA to treat Type II diabetes.

November - The FDA issues a warning about Rezulin (troglitazone). Recommended prescribing information is changed by the drug's manufacturer; new warning label information is added.

December - Approximately 150 adverse events associated with Rezulin have been reported to the FDA.

1998

June - The FDA and Rezulin manufacturer Parke-Davis agree to again tighten restrictions on the use of Rezulin.

July - Parke-Davis sends a letter to heathcare professionals warning to test for liver abnormalities and updating them on the changes in recommended use.

2001

March - Resulin sales are discontinued.